FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281631795> ?p ?o ?g. }

• W4281631795 endingPage "6458" @default.
• W4281631795 startingPage "6458" @default.
• W4281631795 abstract "Breast cancer (BC) is a heterogeneous disease with different intrinsic subtypes. The most aggressive subtype of BC–triple-negative breast cancer (TNBC) is characterized by high heterogeneity and metastasis rate, poor prognosis and lack of therapeutic targets due to the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Targeted therapies have been approved for many other cancers and even other subtypes of BC, but treatment options for TNBC are still mainly limited to chemotherapy. Therefore, new, more effective treatment regimens are needed. Combined chemotherapy with two or more active agents is considered a promising anti-neoplasm tool in order to achieve better therapeutic response and reduce therapy-related adverse effects. The study demonstrated an antagonistic effect commonly used in TNBC therapy cytostatic drug-paclitaxel (PAX) and sirtuin inhibitor: cambinol (CAM) in BT-549, MDA-MB-468 and HCC1937 TNBC cell lines. The type of pharmacological interaction was determined by a precise and rigorous pharmacodynamic method-isobolographic analysis. The cytotoxic and anti-proliferative effects of CAM used alone or combined with PAX were determined utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-bromo-2′-deoxyuridine (BrdU) assays, respectively. Induction of apoptosis in TNBC cell lines after PAX and CAM treatment applied individually or in combination was determined by flow cytometry (FACS) as a number of cells with active caspase-3. It has been observed that both agents used separately inhibit cell proliferation and induce apoptosis; however, applying them in combination ameliorated antiproliferative and pro-apoptotic effects in all analyzed TNBC cell lines. Our results demonstrate that CAM and PAX used in combination act antagonistically, limiting anti-cancer efficacy and showing the importance of preclinical testing." @default.
• W4281631795 created "2022-06-13" @default.
• W4281631795 creator A5033920163 @default.
• W4281631795 creator A5036541627 @default.
• W4281631795 creator A5038671158 @default.
• W4281631795 creator A5064192723 @default.
• W4281631795 creator A5069571990 @default.
• W4281631795 date "2022-06-09" @default.
• W4281631795 modified "2023-09-25" @default.
• W4281631795 title "Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis" @default.
• W4281631795 cites W1789924039 @default.
• W4281631795 cites W1915767302 @default.
• W4281631795 cites W1989493783 @default.
• W4281631795 cites W1998415891 @default.
• W4281631795 cites W2045752636 @default.
• W4281631795 cites W2046711784 @default.
• W4281631795 cites W2050259237 @default.
• W4281631795 cites W2084016080 @default.
• W4281631795 cites W2091309325 @default.
• W4281631795 cites W2098084245 @default.
• W4281631795 cites W2101690600 @default.
• W4281631795 cites W2110197462 @default.
• W4281631795 cites W2122734414 @default.
• W4281631795 cites W2129131491 @default.
• W4281631795 cites W2151615887 @default.
• W4281631795 cites W2162067040 @default.
• W4281631795 cites W2197271423 @default.
• W4281631795 cites W2311002816 @default.
• W4281631795 cites W2335854816 @default.
• W4281631795 cites W2800072713 @default.
• W4281631795 cites W2887606404 @default.
• W4281631795 cites W2973042492 @default.
• W4281631795 cites W2982555156 @default.
• W4281631795 cites W3001950440 @default.
• W4281631795 cites W3025103176 @default.
• W4281631795 cites W3028118646 @default.
• W4281631795 cites W3108834833 @default.
• W4281631795 cites W3138395871 @default.
• W4281631795 cites W3187624116 @default.
• W4281631795 cites W3196979618 @default.
• W4281631795 cites W4200172310 @default.
• W4281631795 cites W4205189087 @default.
• W4281631795 cites W4205229145 @default.
• W4281631795 cites W4206614648 @default.
• W4281631795 cites W4206931709 @default.
• W4281631795 cites W4210291822 @default.
• W4281631795 cites W4213070443 @default.
• W4281631795 cites W4214924946 @default.
• W4281631795 cites W4223576254 @default.
• W4281631795 doi "https://doi.org/10.3390/ijms23126458" @default.
• W4281631795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35742901" @default.
• W4281631795 hasPublicationYear "2022" @default.
• W4281631795 type Work @default.
• W4281631795 citedByCount "3" @default.
• W4281631795 countsByYear W42816317952022 @default.
• W4281631795 countsByYear W42816317952023 @default.
• W4281631795 crossrefType "journal-article" @default.
• W4281631795 hasAuthorship W4281631795A5033920163 @default.
• W4281631795 hasAuthorship W4281631795A5036541627 @default.
• W4281631795 hasAuthorship W4281631795A5038671158 @default.
• W4281631795 hasAuthorship W4281631795A5064192723 @default.
• W4281631795 hasAuthorship W4281631795A5069571990 @default.
• W4281631795 hasBestOaLocation W42816317951 @default.
• W4281631795 hasConcept C121608353 @default.
• W4281631795 hasConcept C126322002 @default.
• W4281631795 hasConcept C190283241 @default.
• W4281631795 hasConcept C2776999253 @default.
• W4281631795 hasConcept C2777292972 @default.
• W4281631795 hasConcept C2779013556 @default.
• W4281631795 hasConcept C2780110267 @default.
• W4281631795 hasConcept C502942594 @default.
• W4281631795 hasConcept C530470458 @default.
• W4281631795 hasConcept C54355233 @default.
• W4281631795 hasConcept C55493867 @default.
• W4281631795 hasConcept C62112901 @default.
• W4281631795 hasConcept C71924100 @default.
• W4281631795 hasConcept C86803240 @default.
• W4281631795 hasConcept C98274493 @default.
• W4281631795 hasConceptScore W4281631795C121608353 @default.
• W4281631795 hasConceptScore W4281631795C126322002 @default.
• W4281631795 hasConceptScore W4281631795C190283241 @default.
• W4281631795 hasConceptScore W4281631795C2776999253 @default.
• W4281631795 hasConceptScore W4281631795C2777292972 @default.
• W4281631795 hasConceptScore W4281631795C2779013556 @default.
• W4281631795 hasConceptScore W4281631795C2780110267 @default.
• W4281631795 hasConceptScore W4281631795C502942594 @default.
• W4281631795 hasConceptScore W4281631795C530470458 @default.
• W4281631795 hasConceptScore W4281631795C54355233 @default.
• W4281631795 hasConceptScore W4281631795C55493867 @default.
• W4281631795 hasConceptScore W4281631795C62112901 @default.
• W4281631795 hasConceptScore W4281631795C71924100 @default.
• W4281631795 hasConceptScore W4281631795C86803240 @default.
• W4281631795 hasConceptScore W4281631795C98274493 @default.
• W4281631795 hasFunder F4320326535 @default.
• W4281631795 hasIssue "12" @default.
• W4281631795 hasLocation W42816317951 @default.
• W4281631795 hasLocation W42816317952 @default.
• W4281631795 hasLocation W42816317953 @default.

• next